Danish health authorities are asking the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition.
The rare eye condition, referred to as non-arteritic anterior ischemic optic neuropathy, (NAION), is an irreversible disease caused by reduced blood flow to the optic nerve. The resulting aftermath is sudden vision loss in type 2 diabetes patients, Reuters reported.
